Results 171 to 180 of about 75,915 (258)

Chimerism and clonal exhaustion [2] (multiple letters) [PDF]

, 1998
Bishop, GA, McCaughan, GW, Shell, AGR, Starzl, T, Sun, J   +4 more
core   +1 more source

Omeprazole Induces CYP3A4 mRNA Expression but Not CYP3A4 Protein Expression in HepaRG Cells.

Biological & pharmaceutical bulletin
Unknown interactions between drugs remain the limiting factor for clinical application of drugs, and the induction and inhibition of drug-metabolizing CYP enzymes are considered the key to examining the drug-drug interaction (DDI). In this study, using human HepaRG cells as an in vitro model system, we analyzed the potential DDI based on the expression
Yuto, Fujita, Takahito, Miyake, Xinyan, Shao, Yuto, Aoki, Emi, Hasegawa, Masao, Doi   +5 more
openaire   +1 more source

Pregnane X Receptor Regulates Human Endocrine System by Inducing Sex Hormone–Binding Globulin Expression

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 4, April 2026.
ABSTRACT Sex hormone–binding globulin (SHBG) is a sex hormone carrier. We aimed to characterize the role of pregnane X receptor (PXR), a major regulator of drug metabolism, in SHBG regulation. Serum SHBG was measured in four clinical trials (n = 61) and expression in in vitro experiments in human 3D hepatocyte spheroids and HepG2 cells.
Maria H. Ahonen, Anja Konzack, Tomas Smutny, Petr Pavek, Jukka Hakkola, Janne Hukkanen   +5 more
wiley   +1 more source

Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy. [PDF]

J Clin Pharmacol
Rodrigues D.
europepmc   +1 more source

Population Pharmacokinetic Model Assessment of the Effects of Body Weight on Risk of Drug–Drug Interactions After Posaconazole Discontinuation

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Posaconazole is a broad‐spectrum triazole antifungal agent indicated for the prophylaxis and treatment of invasive fungal infections. Posaconazole pharmacokinetics and drug–drug interactions (DDIs), due to cytochrome P450 3A4 (CYP3A4) inhibition, have been previously characterized.
Rebecca E. Wrishko, Thomas J. Bateman, Matthew G. Johnson, Prajakti A. Kothare   +3 more
wiley   +1 more source

Donor and recipient genetic polymorphisms modulate tacrolimus pharmacokinetics during voriconazole co-therapy: a drug-drug interaction study in liver transplant recipients. [PDF]

Ther Adv Drug Saf
Li J, Li L, Xia Y, Chen J, Li J, Lin X, Chen X, Tang KJ, Chen P, Liu X.   +9 more
europepmc   +1 more source

Impact of Pharmacokinetic Gene Polymorphisms on Statin‐Induced Myotoxicity in Thai Patients Treated With Simvastatin

Clinical and Translational Science, Volume 19, Issue 4, April 2026.
ABSTRACT Statin‐induced myotoxicity (SIM) is a common adverse effect of simvastatin therapy, which can negatively impact patient adherence and treatment outcomes. This study aims to investigate the impacts of pharmacokinetic (PK) gene polymorphisms on SIM in Thai population treated with simvastatin.
Sayanit Tipnoppanon, Sarawut Siwamogsatham, Yongkasem Vorasettakarnkij, Chonlaphat Sukasem, Pajaree Chariyavilaskul, Patompong Satapornpong, Natchaya Vanwong   +6 more
wiley   +1 more source

Mechanistic insights into atorvastatin-induced hepatotoxicity: molecular pathways, clinical relevance, and strategies for safer personalized therapy. [PDF]

Clin Exp Med
Abdel-Rasol MA, El-Sayed WM.
europepmc   +1 more source

Measuring Direct Oral Anticoagulant (DOAC) Levels: Applications, Limitations, and Future Directions

International Journal of Laboratory Hematology, Volume 48, Issue 2, Page 250-258, April 2026.
ABSTRACT Introduction There are important challenges with the measurement and interpretation of direct oral anticoagulant (DOAC) anticoagulant effect including a lack of therapeutic ranges, inaccuracy of routinely available coagulation assays, lack of established thresholds for clinically significant effect, and uncertainty about how to apply the ...
Siraj Mithoowani, Chee Wee Tan, Deborah M. Siegal   +2 more
wiley   +1 more source

The Effects of Daridorexant on Patients With Comorbid Insomnia Disorder and Untreated Mild Obstructive Sleep Apnoea: A Post Hoc Subgroup Analysis of a Phase 3, Randomised Clinical Trial

Journal of Sleep Research, Volume 35, Issue 2, April 2026.
ABSTRACT Daridorexant, a dual orexin receptor antagonist, is approved for the treatment of insomnia disorder in adults. Approximately 30%–35% of patients with insomnia disorder also have obstructive sleep apnoea (OSA) of any severity. It is unclear whether sleep medications provide safe and effective treatment for insomnia in these patients.
Christopher J. Lettieri, Orestis Briasoulis, Damien Léger, Pierre‐Philippe Luyet, Jean‐Louis Pépin, Stuart F. Quan, Janna Raphelson, Paul Saskin, Atul Malhotra   +8 more
wiley   +1 more source